Clinical trial of the effects of coenzyme Q10 supplementation on glycemic control and markers of lipid profiles in diabetic hemodialysis patients Effects of a New Flavonoid and Myo-Inositol Supplement on Some Biomarkers of Cardiovascular Risk in Postmenopausal Women: A Randomized Trial RRR-alpha-tocopheryl acetate supplementation at pharmacologic doses decreases low-density-lipoprotein oxidative susceptibility but not protein glycation in patients with diabetes mellitus. Lipoprotein profile, plasma Ischemia Modified Albumin and LDL density change in the course of postprandial lipemia. Insights from the LIPGENE study Effect of long-term treatment with antioxidants (vitamin C, vitamin E, coenzyme Q10 and selenium) on arterial compliance, humoral factors and inflammatory markers in patients with multiple cardiovascular risk factors Bergamot polyphenolic fraction enhances rosuvastatin-induced effect on LDL-cholesterol, LOX-1 expression and protein kinase B phosphorylation in patients with hyperlipidemia. Effects of alpha-lipoic acid supplementation on inflammation, oxidative stress, and serum lipid profile levels in patients with end-stage renal disease on hemodialysis. Effect of a dietary intervention and n-3 fatty acid supplementation on measures of serum lipid and insulin sensitivity in persons with HIV. Relationship between serum inositol concentration and development of retinopathy of prematurity: a prospective study. Influence of Low High-Density Lipoprotein Cholesterol and Elevated Triglyceride on Coronary Heart Disease Events and Response to Simvastatin Therapy in 4S Effects of high performance inulin supplementation on glycemic status and lipid profile in women with type 2 diabetes: a randomized, placebo-controlled clinical trial. Effect of alpha-lipoic acid on asymmetric dimethylarginine and disability in multiple sclerosis patients: A randomized clinical trial Plasma lipidomic profiles and cardiovascular events in a randomized intervention trial with the Mediterranean diet. Alpha-Tocopherol Supplementation in Healthy Individuals Reduces Low-Density Lipoprotein Oxidation but Not Atherosclerosis: The Vitamin E Atherosclerosis Prevention Study (VEAPS) Effects of soy supplementation on blood lipids and arterial function in hypercholesterolaemic subjects Effects of a dietary supplement on cholesterol in subjects with moderate hypercholesterolemia. Effects of carnitine and coenzyme Q10 on lipid profile and serum levels of lipoprotein(a) in maintenance hemodialysis patients on statin therapy.
Purpose The current study was conducted to determine the effects of coenzyme Q10 ( CoQ10 ) supplementation on glycemic control and markers of lipid profiles risk in diabetic hemodialysis ( HD ) patients . Methods This r and omized , double blind , placebo-controlled clinical trial was performed among 60 diabetic HD patients . Subjects were r and omly allocated into two groups to take either 120 mg/day of CoQ10 supplements or placebo ( n = 30 each group ) for 12 weeks . Results After 12 weeks of intervention , CoQ10 supplementation , compared with the placebo , result ed in a significant decrease in serum insulin concentrations ( − 2.5 ± 4.0 vs. + 2.8 ± 5.3 µIU/mL , P < 0.001 ) , homeostasis model of assessment -estimated insulin resistance ( − 0.9 ± 2.1 vs. + 1.2 ± 3.0 , P = 0.002 ) , and significant increase in the quantitative insulin sensitivity check index ( + 0.009 ± 0.01 vs. − 0.02 ± 0.05 , P = 0.003 ) . In addition , a trend toward a greater decrease in serum triglycerides ( − 5 ± 53 vs. + 17 ± 44 , P = 0.078 ) and VLDL-cholesterol levels ( − 0.9 ± 10 vs. + 3 ± 9 , P = 0.078 ) was observed in the CoQ10 group compared to the placebo group . We did not observe any significant effect of CoQ10 supplementation on fasting glucose , HbA1c and other lipid profiles compared with the placebo . Conclusions Overall , our study supported that CoQ10 supplementation to diabetic HD patients for 12 weeks had beneficial effects on markers of insulin metabolism , but did not affect fasting glucose , HbA1c , and lipid profiles . Clinical registration http://www.i rct .ir : I RCT 2016081811763N30 Background and Aim . Cardiovascular risk is increased in women with menopause and metabolic syndrome . Aim of this study was to test the effect of a new supplement formula , combining cocoa polyphenols , myo-inositol , and soy isoflavones , on some biomarkers of cardiovascular risk in postmenopausal women with metabolic syndrome . Methods and Results . A total of 60 women were enrolled and r and omly assigned ( n = 30 per group ) to receive the supplement ( NRT : 30 mg of cocoa polyphenols , 80 mg of soy isoflavones , and 2 gr of myo-inositol ) , or placebo for 6 months . The study protocol included three visits ( baseline , 6 , and 12 months ) for the evaluation of glucose , triglycerides , and HDL-cholesterol ( HDL-C ) , adiponectin , visfatin , resistin , and bone-specific alkaline phosphatase ( bone-ALP ) . At 6 months , a significant difference between NRT and placebo was found for glucose ( 96 ± 7 versus 108 ± 10 mg/dL ) , triglycerides ( 145 ± 14 versus 165 ± 18 mg/dL ) , visfatin ( 2.8 ± 0.8 versus 3.7 ± 1.1 ng/mL ) , resistin ( 27 ± 7 versus 32 ± 8 µg/L ) , and b-ALP ( 19 ± 7 versus 15 ± 5 µg/mL ) . No difference in HDL-C concentrations nor in adiponectin levels between groups was reported at 6 months . Conclusions . The supplement used in this study improves most of the biomarkers linked to metabolic syndrome . This Trial is registered with NCT01400724 Patients with diabetes mellitus have an increased risk of premature atherosclerosis , which may be due in part to increased oxidizability of low-density lipoprotein ( LDL ) . Numerous studies have shown that alpha-tocopherol can reduce the oxidative susceptibility of LDL in normoglycemic subjects ; however , there are few studies in persons with diabetes . In addition , alpha-tocopherol may reduce the extent of protein glycation . Therefore , the objective of the present study was to assess the effect of RRR-alpha-tocopheryl acetate supplementation on LDL oxidizability and protein glycation in persons with diabetes without evidence of vascular disease . Twenty-eight persons with insulin-dependent diabetes mellitus ( IDDM ) and non-insulin-dependent diabetes mellitus ( NIDDM ) were r and omly assigned to receive either placebo or 1632 mg ( 1200 IU ) RRR-alpha-tocopherol/d , as tocopheryl acetate , for 8 wk . Plasma and LDL antioxidant concentrations and LDL oxidizability were assessed at both 0 and 8 wk . Plasma and LDL concentrations of alpha-tocopherol were significantly increased in the supplemented group only . Compared with the placebo group , the alpha-tocopherol-supplemented group had significant reductions in LDL oxidizability at 8 wk , as shown by the time-course curves of conjugated diene and lipid peroxide formation . Also , alpha-tocopherol supplementation produced a significant prolongation in the lag phases of both assays , which was evident in both the NIDDM and IDDM subgroups . However , there were no significant changes in glycated hemoglobin or in glycated plasma proteins after alpha-tocopherol supplementation . Thus , alpha-tocopherol supplementation may be beneficial in reducing LDL oxidizability in patients with diabetes Abstract Postpr and ial lipemia is associated with elevated risk of cardiovascular disease . Very little data exists regarding postpr and ial response in subjects with metabolic syndrome ( MetS ) . The current study was conducted within the LIPGENE EU Integrated Project . Patients were r and omized to one of the four isocaloric fatty meals ( Oral Fat Tolerance Tests , OFTT ) : ( A ) high-fat , saturated fatty acid (SFA)-rich ( HFSA ) , ( B ) high-fat , monounsaturated fatty acid (MUFA)-rich ( HFMUFA ) , ( C ) low-fat , high-complex carbohydrate with 1.24 g high oleic sunflower oil supplement ( LFHCC ) and ( D ) low-fat high-complex carbohydrate with 1.24 g long chain n-3 poly-unsaturated fatty acid ( LC n-3 PUFA ) supplement ( LFHCCn-3 ) . The total and incremental areas under the curve ( tAUC and iAUC ) of plasma lipid and lipoprotein , Ischemia Modified Albumin ( IMA ) and LDL density were examined in patients with MetS to define effect of OFTT . All types of OFTT transiently increased plasma triglyceride and LDL density ( LDLdens ) . It was paralleled by temporal decrease in total cholesterol ( TC ) , LDL cholesterol ( LDL-C ) , and HDL cholesterol ( HDL-C ) . This last effect was partly alleviated in LFHCCn-3 test . A reversible increase of IMA was statistically significant only in the course of HSFA and HMUFA tests . EPA and DHA supplement in combined high complex-carbohydrate meal may attenuate adverse effect of tested meal on LDL particle profile and plasma ischemia modified albumin . No expected associations between measures of central adiposity ( waist , WHR ) , adipose tissue insulin resistance ( Adipo-IR ) , and postpr and ial responses of TG , TC , LDL-C , HDL-C , LDLdens and IMA/Alb ratio were found in subgroup analysis . Trial registration : Clinical Trials.gov identifier : NCT00429195 Background Antioxidant supplementations have the potential to alleviate the atherosclerotic damage caused by excessive production of reactive oxygen species ( ROS ) . The present study evaluated the effects of prolonged antioxidant treatment on arterial elasticity , inflammatory and metabolic measures in patients with multiple cardiovascular risk factors . Methods Study participants were r and omly assigned to two groups . Group 1 received oral supplementation with 2 capsules per day of Mid Life Guard , SupHerb , Israel . In each capsule vitamin C ( 500 mg ) vitamin E ( 200 iu ) , co-enzyme Q10 ( 60 mg ) and selenium ( 100 mcg ) , Group 2 received matching placebo(SupHerb ) for 6 months . Patients were evaluated for lipid profile , HbA1C , insulin , C-peptide , hs-CRP , endothelin , aldosterone , plasma renin activity and Homeostasis model assessment -insulin resistance ( HOMA-IR ) . Arterial elasticity was evaluated using pulse wave contour analysis ( HDI CR 2000 , Eagan , Minnesota ) . Results Antioxidant-treated patients exhibited significant increases in large arterial elasticity index ( LAEI ) as well as small arterial elasticity index ( SAEI ) . A significant decline HbA1C and a significant increase in HDL-cholesterol were also observed . In the placebo group , significant changes in LAEI , SAEI or metabolic measures were not observed . Conclusions Antioxidant supplementation significantly increased large and small artery elasticity in patients with multiple cardiovascular risk factors . This beneficial vascular effect was associated with an improvement in glucose and lipid metabolism as well as decrease in blood pressure BACKGROUND Statins are the most commonly prescribed drugs to reduce cardiometabolic risk . Besides the well-known efficacy of such compounds in both preventing and treating cardiometabolic disorders , some patients experience statin-induced side effects . We hypothesize that the use of natural bergamot-derived polyphenols may allow patients undergoing statin treatment to reduce effective doses while achieving target lipid values . The aim of the present study is to investigate the occurrence of an enhanced effect of bergamot-derived polyphenolic fraction ( BPF ) on rosuvastatin-induced hypolipidemic and vasoprotective response in patients with mixed hyperlipidemia . METHODS A prospect i ve , open-label , parallel group , placebo-controlled study on 77 patients with elevated serum LDL-C and triglycerides was design ed . Patients were r and omly assigned to a control group receiving placebo ( n=15 ) , two groups receiving orally administered rosuvastatin ( 10 and 20mg/daily for 30 days ; n=16 for each group ) , a group receiving BPF alone orally ( 1000 mg/daily for 30 days ; n=15 ) and a group receiving BPF ( 1000 mg/daily given orally ) plus rosuvastatin ( 10mg/daily for 30 days ; n=15 ) . RESULTS Both doses of rosuvastatin and BPF reduced total cholesterol , LDL-C , the LDL-C/HDL-C ratio and urinary mevalonate in hyperlipidemic patients , compared to control group . The cholesterol lowering effect was accompanied by reductions of malondialdehyde , oxyLDL receptor LOX-1 and phosphoPKB , which are all biomarkers of oxidative vascular damage , in peripheral polymorphonuclear cells . CONCLUSIONS Addition of BPF to rosuvastatin significantly enhanced rosuvastatin-induced effect on serum lipemic profile compared to rosuvastatin alone . This lipid-lowering effect was associated with significant reductions of biomarkers used for detecting oxidative vascular damage , suggesting a multi-action enhanced potential for BPF in patients on statin therapy OBJECTIVE We examined the effects of alpha-lipoic acid ( ALA ) supplementation on inflammation , oxidative stress , and serum lipid profile levels in hemodialysis ( HD ) patients . DESIGN This was a double-blinded , r and omized , placebo-controlled clinical trial . SETTING The present study involved HD centers in Tabriz , Iran . PATIENTS Participants included 63 patients with end-stage renal disease ( 43 men and 20 women ; age range : 22 - 79 years ) undergoing maintenance HD . INTERVENTION HD patients were r and omly assigned into the supplemented group ( n = 31 ) , receiving a daily dose of ALA ( 600 mg ) , or a control group ( n = 32 ) , receiving placebo for 8 weeks . MAIN OUTCOME MEASURES High sensitivity C-reactive protein ( hsCRP ) , malondialdehyde , total antioxidant status , total cholesterol , triglyceride , high-density lipoprotein cholesterol ( HDL-C ) , and low-density lipoprotein cholesterol ( LDL-C ) were measured at baseline and after 8 weeks of supplementation . RESULTS At the end of intervention , 11 patients were excluded from the study .  HsCRP levels decreased by 18.7 % in the supplemented group after 8 weeks of supplementation , and the reduction was significant in comparison with the placebo group ( P < .05 ) ; this finding was also significant after adjusting for baseline values of hsCRP . The mean malondialdehyde and total antioxidant status levels did not change significantly in the 2 groups during the study . The mean high-density lipoprotein cholesterol concentrations increased significantly in the supplemented group at the end of the study ( P < .05 ) ; however , this improvement was not statistically significant as compared with the placebo group . No significant alterations were observed in the other lipid profile parameters within each group during the study . CONCLUSION ALA supplementation significantly reduced hsCRP levels , which is a risk factor for cardiovascular disease in HD patients BACKGROUND Elevated serum triglyceride and low HDL-cholesterol concentrations have been reported in persons with HIV . OBJECTIVE The effect of a dietary intervention plus n-3 ( omega-3 ) fatty acid supplementation on serum triglycerides and markers of insulin sensitivity was investigated . DESIGN Fifty-four persons with HIV and elevated serum triglycerides ( > 150 mg/dL ) and /or abnormal Quantitative Insulin Sensitivity Check Index values ( < 0.35 but > 0.30 ) were recruited for a dietary intervention in which total fat , type of fat , fiber , and glycemic load were controlled along with supplementation with n-3 fatty acids to achieve an intake of 6 g/d . The subjects were r and omly assigned to an intervention or control group , and serum lipids , markers of insulin sensitivity , and serum phospholipid fatty acids were measured in both groups at baseline , 3 wk , and 13 wk . RESULTS Triglycerides in the intervention group decreased from a median of 180 mg/dL ( interquartile range : 141 , 396 ) to 114 mg/dL ( interquartile range : 84 , 169 ) from baseline to 3 wk , whereas they remained stable in the control group ( P = 0.003 ) . Serum phospholipid fatty acids indicated a decrease in de novo lipogenesis and a decrease in arachidonic acid ( % nmol ; P < or= 0.001 ) in the intervention group . At 3 wk , the insulin area under the curve decreased but not significantly . CONCLUSIONS Diet and n-3 fatty acid supplementation dramatically reduced serum triglycerides , decreased arachidonic acid in the phospholipids fraction , and appeared to decrease the de novo lipogenesis associated with the metabolic syndrome in the intervention group PURPOSE To examine the relationship between the intake of sugar inositol , serum inositol levels , and ROP in three groups of low birthweight infants receiving feedings containing various concentrations of inositol .  METHODS Infants with a birthweight < 1500 g , with severe lung disease , were eligible for the study when they began enteral feedings . Infant formulas contained three different inositol concentrations : 2500 , 710 , and 242 micromol/L. Serum inositol concentrations were averaged over specific time intervals . A logistic regression model was used to investigate the confounding effect of duration of mechanical ventilation and oxygen therapy , birthweight , Apgar score , and serum inositol concentration on development of ROP . RESULTS Infants receiving high inositol formula and with higher serum inositol concentrations at birth and after 30 days had a statistically significant lower incidence of severe ROP than those receiving the lower inositol formula and with lower serum concentrations ( P<.05 ) . The effective serum inositol concentration ( EC90 ) associated with lesser disease was > 215 micromol/L. By logistic regression , the odds of developing severe ROP were greater among infants with low serum inositol concentration ( odds ratio=4.7 , 95 % confidence interval 0.90 - 24.8 , P=.017 ) . CONCLUSION Inositol supplementation may help prevent the most severe form of ROP Background — Patients with low HDL cholesterol ( HDL-C ) and elevated triglyceride had an increased  risk for coronary heart disease ( CHD ) events and received the greatest benefit with fibrate therapy in sub study analyses of the Helsinki Heart Study and the Bezafibrate Infa rct ion Prevention Study . Methods and Results —In this post hoc analysis of the Sc and inavian Simvastatin Survival Study , which enrolled patients with elevated LDL cholesterol ( LDL-C ) and CHD , subgroups defined by HDL-C and triglyceride quartiles were compared to examine the influence of HDL-C and triglyceride on CHD events and response to therapy . Patients in the lowest HDL-C ( < 1.00 mmol/L [ 39 mg/dL ] ) and highest triglyceride ( > 1.80 mmol/L [ 159 mg/dL ] ) quartiles ( lipid triad ; n=458 ) had increased proportions of other features of the metabolic syndrome ( increased body mass index , hypertension , diabetes ) , men , prior myocardial infa rct ion , prior revascularization , and & bgr;-blocker use than patients in the highest HDL-C ( > 1.34 mmol/L [ 52 mg/dL ] ) and lowest triglyceride ( < 1.11 mmol/L [ 98 mg/dL ] ) quartiles ( isolated LDL-C elevation ; n=545 ) . The major coronary event rate was highest in lipid triad patients on placebo ( 35.9 % ) , and this subgroup had the greatest event reduction ( relative risk 0.48 , 95 % CI 0.33 to 0.69 ) ; a significant treatment-by-subgroup interaction ( P = 0.03 ) indicated a greater treatment effect in the lipid triad subgroup than the isolated LDL-C elevation subgroup . Conclusions — Patients with elevated LDL-C , low HDL-C , and elevated triglycerides  were more likely than patients with isolated LDL-C elevation to have other characteristics of the metabolic syndrome , had increased risk for CHD events on placebo , and received greater benefit with simvastatin therapy BACKGROUND Type 2 diabetes mellitus , as a noncommunicable disease , is the main public health challenge in the 21st century . The prevalence of diabetes mellitus adjusted for the world population in Iran was 8 % until the year 2010.Lipid levels are considered as important parameters to be evaluated , as high serum lipid levels are often reported as a complication in patients with diabetes mellitus . It is cl aim ed that functional foods may improve complications of diabetes mellitus , so this study was design ed to evaluate the effects of high performance inulin on glycemic status and lipid profile of women with type 2 diabetes . METHODS The study was a r and omized controlled clinical trial . Forty-nine type 2 diabetic females ( fiber intake < 30g/d , 25 < BMI < 35 kg/m2 ) were divided into two groups . Patients in the intervention group ( n=24 ) received 10g/d inulin and patients in the control group ( n=25 ) received 10g/d maltodextrin for 8 weeks .  Glycemic status and lipid profile indices were measured pre and post intervention . Data were analyzed using SPSS software ( verision11.5 ) . Paired , unpaired t-test and ANCOVA were used to compare quantitative variables . RESULTS Supplementation with inulin caused a significant reduction in FBS ( 8.50 % ) , HbA1c ( 10.40 % ) , total cholesterol ( 12.90 % ) , triglyceride ( 23.60 % ) , LDL-c ( 35.30 % ) , LDL-c/HDL-c ratio ( 16.25 % ) and TC/HDL-c ratio ( 25.20 % ) and increased HDL-c ( 19.90 % ) . The changes for the control group parameters were not significant at the end of study . CONCLUSION Inulin may help to control diabetes and its complications via improving glycemic and lipid parameters Background Multiple Sclerosis ( MS ) is an inflammatory and demyelinating disease of the central nervous system . Oxidative stress plays a major role in the onset and progression of MS . Asymmetric dimethylarginine ( ADMA ) formation is dependent on oxidative stress status . Objective We examined whether alpha-lipoic acid ( ALA ) as a potent antioxidant could improve the Exp and ed Disability Status Scale ( EDSS ) and decrease plasma level of ADMA in multiple sclerosis patients . Methods In a r and omized , double-blinded clinical trial conducted at Sina Hospital in Tehran , Iran , from September 2009 to July 2011 , 24 patients with relapsing-remitting MS were divided into a treatment group receiving ALA ( 1200mg/day ) for 12 weeks and a control group receiving placebo . Then patients ’ EDSS and Plasma levels of ADMA were measured at baseline and 12 weeks later . Statistical analysis was done by SPSS software version 16 using the K-S test , Chi square , Mann – Whitney U-test and Wilcoxon test . Results The plasma levels of ADMA in the intervention group were decreased significantly ( p=0.04 ) . Also , no patient had increased EDSS score in the supplement group , where 2 out of 12 patients in the placebo group experienced so . Comparing the serum level of ADMA between the two groups failed to show any significant change in the supplement group compared with the control group . Conclusion Considering that ADMA is produced by oxidative stress in MS patients and leads to increase of inflammation , ALA may have the potential of beneficial effects in them , in part , by decreasing the plasma level of ADMA and stopping progression . Trial registration The trial was registered at the Iranian Registry of Clinical Trials ( http://www.i rct .ir ) with the I rct ID : No. I RCT 138812222602N2 . Funding The authors received no financial support for the research , authors hip , and /or publication of this article Background : Lipid metabolites may partially explain the inverse association between the  Mediterranean diet ( MedDiet ) and cardiovascular disease ( CVD ) . Objective : We evaluated the associations between 1 ) lipid species and the risk of CVD ( myocardial infa rct ion , stroke , or cardiovascular death ) ; 2 ) a MedDiet intervention [ supplemented with extra virgin olive oil ( EVOO ) or nuts ] and 1-y changes in these molecules ; and 3 ) 1-y changes in lipid species and subsequent CVD . Design : With the use of a case-cohort design , we profiled 202 lipid species at baseline and after 1 y of intervention in the PREDIMED  ( PREvención con DIeta MEDiterránea ) trial in 983 participants [ 230 cases and a r and om subcohort of 790 participants ( 37 overlapping cases ) ] . Results : Baseline concentrations of cholesterol esters ( CEs ) were inversely associated with CVD . A shorter chain length and higher saturation of some lipids were directly associated with CVD . After adjusting for multiple testing , direct associations remained significant for 20 lipids , and inverse associations remained significant for 6 lipids . When lipid species were weighted by the number of carbon atoms and double bonds , the strongest inverse association was found for CEs [ HR : 0.39 ( 95 % CI : 0.22 , 0.68 ) ] between extreme quintiles ( P-trend = 0.002 ) . Participants in the MedDiet + EVOO and MedDiet + nut groups experienced significant ( P < 0.05 ) 1-y changes in 20 and 17 lipids , respectively , compared with the control group . Of these changes , only those in CE(20:3 ) in the MedDiet + nuts group remained significant after correcting for multiple testing . None of the 1-y changes was significantly associated with CVD risk after correcting for multiple comparisons . Conclusions : Although the MedDiet interventions induced some significant 1-y changes in the lipidome , they were not significantly associated with subsequent CVD risk . Lipid metabolites with a longer acyl chain and higher number of double bonds at baseline were significantly and inversely associated with the risk of CVD Background —Epidemiological studies have demonstrated an inverse relationship between vitamin E intake and cardiovascular disease ( CVD ) risk . In contrast , r and omized controlled trials have reported conflicting results as to whether vitamin E supplementation reduces atherosclerosis progression and CVD events . Methods and Results —The study population consisted of men and women ≥40 years old with an LDL cholesterol level ≥3.37 mmol/L ( 130 mg/dL ) and no clinical signs or symptoms of CVD . Eligible participants were r and omized to DL-&agr;-tocopherol 400 IU per day or placebo and followed every 3 months for an average of 3 years . The primary trial end point was the rate of change in the common carotid artery far-wall intima-media thickness ( IMT ) assessed by computer image-processed B-mode ultrasonograms . A mixed effects model using all determinations of IMT was used to test the hypothesis of treatment differences in IMT change rates . Compared with placebo , & agr;-tocopherol supplementation significantly raised plasma vitamin E levels ( P < 0.0001 ) , reduced circulating oxidized LDL ( P = 0.03 ) , and reduced LDL oxidative susceptibility ( P < 0.01 ) . However , vitamin E supplementation did not reduce the progression of IMT over a 3-year period compared with subjects r and omized to placebo . Conclusions —The results are consistent with previous r and omized controlled trials and extend the null results of vitamin E supplementation to the progression of IMT in healthy men and women at low risk for CVD Background : Studies on soy supplementation suggest a cardioprotective potential . Objective : To examine the effects on LDL cholesterol and arterial function as a result of dietary enrichment with soy supplementation . Design : A R and omized , double blind , parallel intervention trial . Setting : Department of Endocrinology and Metabolism C , Aarhus University Hospital , and Department of Human Nutrition , The Royal Veterinary and Agricultural University , Denmark . Subjects : In all , 100 hypercholesterolaemic but otherwise healthy subjects were included in the study of which 89 completed it . Interventions : Subjects were r and omly assigned to 24 weeks of daily intake of either a soy supplement , Abalon ® ( 30 g soy protein , 9 g cotyledon fibre and 100 mg isoflavones ) or placebo ( 30 g of casein ) . The soy supplement and placebo were provided in two sachets daily that were stirred in water . Fasting plasma lipids , TNF-α , homocysteine , insulin sensitivity , homeostasis model assessment ( HOMA-IR ) , serum insulin , serum glucose , blood pressure as well as Glucagon-like peptide 1 ( GLP-1 ) , glucose-dependent insulinotropic peptide ( GIP ) and plasma lipids to a fat-rich meal were recorded before and after the intervention . In a sub study in 32 subjects , arterial dilatory capacity , compliance , and distensibility were recorded before and after the intervention . Results : In the main study , no difference in fasting plasma lipid levels or insulin sensitivity was found between soy-based supplement and placebo . A significant postpr and ial increase in GIP to the meal test was observed in the soy group ( P<0.05 ) . In a sub study , no difference between the groups in changes in flow-mediated vasodilatation ( P=0.84 ) was detected , while the soy supplementation caused a reduction in LDL and total cholesterol . Conclusions : No significant effects on blood lipids were observed in the main study to a soy supplementation in hypercholesterolaemic subjects after 24 weeks . In the sub study , the soy supplementation , however , reduced LDL and total cholesterol but did not influence markers of arterial function . Sponsorship : Nutri Pharma ASA , Oslo , Norway BACKGROUND AND AIMS Prospect i ve studies have demonstrated that the risk of death due to ischaemic heart disease is strongly correlated with blood cholesterol ( TC ) levels . Diet is the basic treatment for all dyslipidaemia . If diet alone proves inadequate , supplements can be used to try to reduce cholesterol levels . These substances are indicated in moderate dyslipidaemia , as they are able to induce a moderate reduction in blood cholesterol . The objective of our study was to investigate the effects of a dietary supplement containing Omega-3 , Policosanol , Resveratrol , L-carnitine , Monascus purpureus , Coenzyme Q10 , Vitamin B6 and Vitamin B12 on TC ( primary end point ) and LDL , triglycerides and HDL ( secondary endpoints ) . PATIENTS AND METHODS The study involved 40 men and 40 women recruited from the outpatient section of our Department r and omly assigned to the treatment group ( A ) or the control group ( B ) . RESULTS There was a statistically significant reduction in TC 6 months after the end of treatment in both groups . In Group A , there was also a statistically significant change in HDL , LDL and TG , while in group B , there was no statistically significant change in HDL , LDL or TG . CONCLUSIONS The dietary supplement used in our study , in combination with a balanced diet and physical exercise , was found to induce a significant reduction in TC and LDL-C and an improvement in HDL-C. In contrast , while a balanced diet together with physical exercise but without the dietary supplement produced a significant reduction in TC , it had no significant effect on the other lipid parameters tested INTRODUCTION Dyslipidemia and high serum lipoprotein(a ) are among the risk factors for cardiovascular diseases in hemodialysis patients .  Statins as a first line of therapy in hyperlipidemia does not always reduce the serum lipoprotein(a ) level . Several studies have reported the lipid-lowering effects of carnitine and coenzyme Q10 in hemodialysis patients . This study was design ed to investigate the effects of carnitine and coenzyme Q10 on serum lipid profile and lipoprotein(a ) level in maintenance hemodialysis patients . MATERIAL S AND METHODS This was a r and omized placebo-controlled trial . We studied on hemodialysis patients who were on treatment with atorvastatin or lovastatin to assess the efficacy of supplement therapy . They were divided into 4 groups to receive carnitine , coenzyme Q10 , both carnitine and coenzyme Q10 , and placebo . After a 3-month experiment , blood sample s were collected to measure serum levels of lipoprotein(a ) , triglyceride , total cholesterol , high-density lipoprotein cholesterol and low-density lipoprotein cholesterol . RESULTS Fifty-two hemodialysis patients , 27 men and 25 women , completed the course of the study . Three months after supplement therapy , serum levels of lipoprotein(a ) reduced significantly in the carnitine , coenzyme Q10 , and combination groups compared to the baseline values and the 3-month value of lipoprotein(a ) in the placebo group ( P = .01 ) . Serum levels of triglyceride and other lipoproteins did not significantly alter . CONCLUSIONS Our study showed that supplementation with carnitine and coenzyme Q10 could reduce serum levels of lipoprotein(a ) in maintenance hemodialysis patients treated with statins
Conclusions Inositol supplementation may result in reduction in triglycerides , total- and LDL-cholesterol levels , but did not affect HDL-cholesterol levels  among patients with metabolic diseases .
Background Several studies have evaluated the effect of inositol supplementation on lipid profiles among population with metabolic diseases ; however , the findings are controversial .
This review of r and omized controlled trials ( RCTs ) was performed to summarize the evidence of the effects of inositol supplementation on lipid profiles among population with metabolic diseases .